Triple-negative breastcancer (TNBC), which accounts for approximately20% of breast cancer cases, is a particular subtype that lacks theexpression of human epidermal growth factor receptor 2 (HER2), estrogenreceptor (ER), or progesterone receptor (PR).1 In general, TNBC is biologically aggressive since it is highly proliferativeand is the subtype with the poorest prognosis due to its highly malignantnature.2 Although the development of alternativetherapeutics has continued over the last decades, chemotherapy remainsthe major approach for systemic treatment of TNBC nowadays. This evidence concerns the gene ESR1 and breast carcinoma.